Women with early-stage breast cancer who receive a shorter course of whole breast radiation therapy experience less toxicity and improved quality of life compared to those who undergo a longer course of treatment. The study suggests that hypofractionated treatment should be considered as a starting point for discussion between patients...
Scientists at MD Anderson Cancer Center discovered the critical role of fumarase enzyme in DNA repair, revealing a key mechanism for reversing genetic damage leading to cancer and therapy resistance. The study's findings have potential implications for developing new cancer treatments by inhibiting DNA-PKs and fumarase.
Scientists at University of Texas MD Anderson Cancer Center identified EMT as a potential therapeutic target for reversing kidney disease and fibrosis. The study showed that inhibiting EMT in tubular epithelial cells can restore their health and function.
The MD Anderson Cancer Center has been selected as a Genome Characterization Center to analyze patient samples from multiple NCI programs. The center will focus on functional proteomics, enabling the study of protein expression and modification in cancer tumors.
Researchers found that 35% of patients with early-onset colorectal cancer (diagnosed before age 35) have a genetic disease, highlighting the need for genetic counseling to identify high-risk family members. Gene panel testing is recommended to uncover underlying mutations, allowing for preventive measures and earlier screening.
A new study by MD Anderson researchers found that protein 14-3-3 sigma opposes and reverses tumor-promoting metabolic programs in breast cancer. The study revealed that 14-3-3 sigma suppresses cancer glycosis, preventing tumors from converting glucose into pyruvate.
MD Anderson researchers discovered a breast tumor marker that predicts metastasis by analyzing the gene expression signature of mouse embryos. Tumors with similar signatures to six-day-old embryos were more prone to metastasize than those with adult-like signatures.
Researchers at MD Anderson Cancer Center have identified a potential non-invasive diagnostic tool for early pancreatic cancer detection. Glypican-1-enriched circulating exosomes were found to be present in small amounts of serum from patients with pancreatic cancer, showing high specificity and sensitivity. Early detection of pancreati...
Current blood cancer drug prices are too high to be considered cost-effective in the US, according to a recent MD Anderson Cancer Center study. The researchers found that 63% of 20 studies evaluated had costs per additional life-year higher than $50,000, indicating that current prices cannot be justified based on improved quality of life.
Researchers identified four melanoma subtypes, including BRAF, RAS, NF1 and Triple-WT, through analysis of 331 patient samples. These subtypes share common signaling pathways but differ in activation, suggesting potential for targeted therapies.
The study found that breast-conserving therapy (BCT) is being used more widely, with a steady increase in rates over the last 13 years. However, disparities persist, particularly among patients without insurance or those living far from treatment facilities.
A recent study by MD Anderson researchers identified DAPK1 as a novel therapeutic target for breast and other cancers with TP53 mutations. High levels of DAPK1 are associated with poor prognosis and increased cancer growth in these tumors.
Researchers found that mutations in ARID1a gene sensitize certain tumors to PARP inhibitor drugs, allowing for more effective treatment options. The study highlights the importance of using genomic information to guide cancer therapy and identify precise treatments for individual patients.
A new way of classifying brain cancers has been found, with striking molecular differences between various forms of gliomas. This discovery could lead to more precise diagnosis and patient management.
Researchers discovered that TLR4 can function as a growth suppressor in wild-type TP53 cells but promotes growth in TP53 mutant cells. This balance affects survival rates and treatment outcomes.
A large study has found that whole brain radiation therapy (WBRT) significantly worsens cognitive function compared to radiosurgery, and should no longer be used in the adjuvant setting after radiosurgery. WBRT's side effects include hair loss, fatigue, and significant interruptions in systemic therapy.
A study has identified a possible new combination chemotherapy regimen for patients with advanced metastatic castrate-resistant prostate cancer. The treatment, combining cabazitaxel and carboplatin, significantly extended progression-free survival by 2.3 months compared to single-agent therapy.
Jim Allison's pioneering work on T-cell response mechanisms led to the development of ipilimumab, a melanoma treatment that has shown unprecedented results in survival rates. His research continues to open new avenues for cancer treatment through immune checkpoint blockade.
Researchers at MD Anderson Cancer Center have identified a biomarker that may boost the response to chemotherapy in patients with ovarian cancer. The study found that miR-506 was associated with improved responses to chemotherapy drugs cisplatin and olaparib, leading to better overall survival.
A recent study from the University of Texas MD Anderson Cancer Center suggests that profiling normal DNA provides an opportunity to identify inherited mutations critical for patients and their families. Researchers sequenced tumor and normal DNA from patients with advanced cancer, identifying germline mutations in nearly all cases.
A phase III randomized clinical trial suggests that Stereotactic Ablative Radiotherapy (SABR) is equally effective to surgery in treating operable stage I non-small cell lung cancer patients, with better survival rates and lower toxicity. SABR appears to be a suitable alternative for elderly and comorbidity-prone patients.
Researchers found that hepatitis B patients develop HCC at a younger age with more aggressive disease, while hepatitis C patients have underlying cirrhosis and diabetes. The study highlights the need to consider hepatitis status when developing treatment plans for newly diagnosed patients.
Researchers at The University of Texas MD Anderson Cancer Center found that blocking FGL2 protein could potentially treat brain cancer. By modulating the immune system's checkpoints, FGL2 promotes tumor growth and suppresses the immune response.
Researchers discovered a direct link between telomere degeneration and myelodysplastic syndromes (MDS), a group of blood cell disorders. The study found that DNA damage caused by dysfunctional telomeres resulted in repressed expression of the RNA splicing gene SRSF2, affecting CMPs' ability to differentiate.
Researchers found that a toxic mushroom-based drug can suppress the POLR2A gene in cancer cells, resulting in complete tumor regression and reduced toxicity. The study's findings provide a new therapeutic approach for human cancers with common genomic alterations.
Researchers at MD Anderson Cancer Center found that CCAT2, a long non-coding RNA, regulates cancer metabolism in both human samples and animal models. This regulation appears to be linked to an increased risk of colon cancer, suggesting potential new targets for cancer treatment.
Researchers found that patients with anti-TP53 autoantibodies can detect ovarian cancer up to 13 months before rising CA125 levels. The study suggests a novel assay method for earlier detection of the disease.
Researchers from MD Anderson Cancer Center are part of two new Stand Up to Cancer Dream Teams focused on lung cancer driven by KRAS mutations and preventing high-risk ovarian cancer. The teams aim to test combination therapies and launch prevention efforts.
Researchers at MD Anderson Cancer Center have uncovered a novel mechanism by which the tumor suppressor gene p53 regulates PD-L1, allowing non-small cell lung cancer to grow. MicroRNA delivery with existing treatments may represent a new therapeutic approach for lung cancer.
Researchers at MD Anderson Cancer Center identified three subsets of lung cancer with KRAS gene mutations, each with unique signaling patterns and susceptibility to different therapeutic strategies. These subsets may offer new approaches for treating lung adenocarcinoma, the most common form of lung cancer.
James Allison, a renowned immunologist, has been recognized for his pioneering discovery that blocking CTLA-4 improves antitumor immune responses. His work led to the development of ipilimumab, an immune checkpoint inhibitor that transformed melanoma treatment.
Researchers at the University of Texas MD Anderson Cancer Center review the potential of combining genomically targeted therapies with immune checkpoint blockade drugs to attack cancer. The approach shows promise, but more support is needed to accelerate progress and minimize side effects.
A new review emphasizes the need to decipher immune response dynamics to enhance cancer immunotherapy. Researchers suggest developing combination therapies and biomarker panels to increase treatment impact, as single biomarkers are unlikely to predict patient responses.
Scientists at MD Anderson Cancer Center discovered a vital connection between the Hippo pathway and glucose metabolism, which can be manipulated to regulate tumor growth. The study found that regulating blood sugar levels impacts the nutrient source of tumors, ultimately leading to cancer suppression.
Scientists at MD Anderson Cancer Center have discovered a key DNA pathway that allows certain brain cancers to resist standard treatments. The study found that activation of this pathway leads to enhanced survival of tumor cells and increased DNA repair, contributing to treatment resistance.
The Anderson Algorithm increases surgical success in advanced ovarian cancer by providing a personalized approach to surgery, resulting in high complete resection rates of over 86%. This milestone is strongly tied to improved survival outcomes for patients.
Researchers at MD Anderson Cancer Center have identified unique 'protein patterns' in melanoma patients to predict resistance to BRAF inhibitors. These patterns may help guide personalized treatment decisions, including targeted agents or immunotherapies.
The University of Texas MD Anderson Cancer Center has received over $22 million in CPRIT research grants to study breast, skin, prostate, and lung cancers, as well as leukemia and brain cancer. The funding will also support prevention and early detection efforts.
Researchers at MD Anderson Cancer Center found that targeting pericytes and angiopoietin-2 signaling may reduce breast cancer tumor growth and metastasis. The study suggests a potential new therapeutic approach for metastatic breast cancer.
A study by Menashe Bar-Eli and colleagues found that a lack of RNA editing contributes to melanoma tumor growth and metastasis by manipulating proteins. The researchers identified a previously unknown target for CREB, a transcription factor involved in melanoma development.
In a Phase III study, lenvatinib showed dramatic improvement in progression-free survival for patients with advanced radioiodine-refractory thyroid cancer. The therapy significantly improved overall response rate and survival rates compared to placebo.
Researchers found that collagen cross-links play a crucial role in regulating stromal stiffness and determining tumor cell metastatic fate. The study identified two types of collagen cross-links, HLCC and LCC, which are associated with different levels of tumor growth and spread.
A study by MD Anderson researchers identified eight physical and cognitive signs associated with imminent death in cancer patients. These signs include nonreactive pupils, decreased response to verbal and visual stimuli, and upper gastrointestinal bleeding, which could help clinicians communicate with patients and families, as well as ...
A new study explains how a protein that suppresses tumors can also promote metastasis in breast cancer cells. Researchers found that 14-3-3 zeta destabilizes key proteins p53 and GLi2, switching off TGF-β's tumor-suppressing abilities while promoting cancer spread.
A recent study published in JAMA Surgery found that patients with metastatic colorectal cancer are experiencing a decrease in primary tumor resection rates. Despite this decrease, overall survival rates for these patients have improved, indicating potential overutilization of surgery in certain patient populations.
Researchers have successfully treated patients with advanced CD19-positive hematologic malignancies using CAR T cells, achieving complete remission in some cases. The study used the Sleeping Beauty non-viral transduction system to modify T cells, demonstrating further promise in treating lymphoid malignancies.
A study at MD Anderson Cancer Center found PRM-151 to be well-tolerated in patients with advanced myelofibrosis, showing encouraging trends in clinical and histologic aspects of the disease. The therapy demonstrated reduced bone marrow fibrosis and improved hematologic parameters, suggesting potential for further development.
Researchers at MD Anderson Cancer Center discovered that targeting the non-coding microRNA miR569 can increase cell death in ovarian and breast cancers. The study also found that silencing miR569 expression improves survivability outcomes for ovarian patients.
A phase two study demonstrated that a combination of azacitidine and lenalidomide is an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia. The therapy was well tolerated in the study of 88 patients.
A phase three study has demonstrated increased survival rates among AML patients who relapse, with combination therapy employing cytarabine and vosaroxin showing significant benefits. Patients over 60 years old experienced the greatest overall survival benefit from the treatment.